Genome-wide Association Study of Clinical Features in the Schizophrenia Psychiatric Genomics Consortium: Confirmation of Polygenic Effect on Negative Symptoms
Roseann E Peterson,
Richard L. Amdur,
Pablo V. Gejman,
Douglas F Levinson,
David St. Clair,
James TR Walters,
Roel A Ophoff,
Patrick F. Sullivan,
Michele T Pato,
Ole A. Andreassen,
Michael J Owen,
Michael C O'Donovan,
Anil K. Malhotra,
Bryan J Mowry,
Schizophrenia Working Group of the Psychiatric Genomics Consortium,
Ayman H Fanous
Posted 09 Jul 2017
bioRxiv DOI: 10.1101/161349
Posted 09 Jul 2017
Schizophrenia is a clinically heterogeneous disorder. Proposed revisions in DSM-5 included dimensional measurement of different symptom domains. We sought to identify common genetic variants influencing these dimensions, and confirm a previous association between polygenic risk of schizophrenia and the severity of negative symptoms. The Psychiatric Genomics Consortium study of schizophrenia comprised 8,432 cases of European ancestry with available clinical phenotype data. Symptoms averaged over the course of illness were assessed using the OPCRIT, PANSS, LDPS, SCAN, SCID, and CASH. Factor analyses of each constituent PGC study identified positive, negative, manic, and depressive symptom dimensions. We examined the relationship between the resultant symptom dimensions and aggregate polygenic risk scores indexing risk of schizophrenia. We performed genome-wide association study (GWAS) of each quantitative traits using linear regression and adjusting for significant effects of sex and ancestry. The negative symptom factor was significantly associated with polygene risk scores for schizophrenia, confirming a previous, suggestive finding by our group in a smaller sample, though explaining only a small fraction of the variance. In subsequent GWAS, we observed the strongest evidence of association for the positive and negative symptom factors, with SNPs in RFX8 on 2q11.2 (P=6.27×10-8) and upstream of WDR72/UNC13C on 15q21.3 (P=7.59×10-8), respectively. We report evidence of association of novel modifier loci for schizophrenia, though no single locus attained established genome-wide significance criteria. As this may have been due to insufficient statistical power, follow-up in additional samples is warranted. Importantly, we replicated our previous finding that polygenic risk explains at least some of the variance in negative symptoms, a core illness dimension.
- Downloaded 789 times
- Download rankings, all-time:
- Site-wide: 41,688
- In genetics: 1,774
- Year to date:
- Site-wide: 121,426
- Since beginning of last month:
- Site-wide: 83,635
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!